Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
British Journal of Clinical Pharmacology(1)
Clinical Pharmacology and Therapeutics(1)
European Journal of Clinical Pharmacology(1)
Journal of Neurology Neurosurgery and Psychiatry(1)
Orvosi hetilap(1)
Área temáticas
Farmacología y terapéutica(6)
Enfermedades(3)
Bioquímica(1)
Fisiología humana(1)
Fisiología y materias afines(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(7)
ODS 10: Reducción de las desigualdades(5)
ODS 12: Producción y consumo responsables(1)
ODS 17: Alianzas para lograr los objetivos(1)
Origen
scopus(7)
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusAssessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusInteraction between prajmaline and metoprotol: a possible pharmacogenetic explanation
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Berecz R.Fuentes:scopusUse of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
ArticleAbstract: Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. TwoPalabras claves:CYP2D6, High-pressure liquid chromatography, pharmacogenetics, Therapeutic drug monitoring (TDM), ThioridazineAutores:Adrián LLerena, Benitez Rodriguez J., Berecz R., De la Rubia A., Norberto M.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopusReproducibility over Time of Mephenytoin and Debrisoquine Hydroxylation Phenotypes
ArticleAbstract: Mephenytoin and debrisoquine hydroxylation phenotypes were determined twice in 15 Spanish healthy voPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Valdivielso M.J.Fuentes:scopus